Although Iniparib has a poor track record of failure, PARP inhibitors have returned to the breast cancer arena after breaking through the ovarian cancer barrier, with Olaparib and Talazoparib succeeding in single-drug therapy for patients with advanced metastatic disease [2-3].

However, in breast cancer, PARP inhibitors tend to fight the most lethal triple-negative breast cancer, which is the most common subtype of patients with BRCA1 deficiency. Although single drug treatment can be successful, is the efficacy maximized?After being attacked, you may have a better choice in the drug program.

Niraparib, a rising star of PARP inhibitors, is proof of this.Preliminary results from the TOPACIO/KEYNOTE 162 trial showed that Niraparib combined with Pembrozulimab (K) resulted in an objective response rate of 29% in patients with triple-negative breast cancer, and not limited to patients with brca1/2 gene defects [4].

The effect of different pharmacological characteristics on the efficacy of different drugs is also reflected in the clinical exploration of the fight against breast cancer. For example, Talazoparib and Veliparib are both successful and unsuccessful in the same neoadjuvant therapy [5]. Therefore, in the treatment of breast cancer, who laughs last laughs best.
Of course, PARP inhibitors should not only benefit women, but also gender equality.

Post time: May-28-2020